DK0745094T3 - Superagonister og antagonister mod human IL-6 og fremgangsmåder til deres udvælgelse - Google Patents

Superagonister og antagonister mod human IL-6 og fremgangsmåder til deres udvælgelse

Info

Publication number
DK0745094T3
DK0745094T3 DK95940409T DK95940409T DK0745094T3 DK 0745094 T3 DK0745094 T3 DK 0745094T3 DK 95940409 T DK95940409 T DK 95940409T DK 95940409 T DK95940409 T DK 95940409T DK 0745094 T3 DK0745094 T3 DK 0745094T3
Authority
DK
Denmark
Prior art keywords
site
superantagonists
interleukin
superagonists
hormone
Prior art date
Application number
DK95940409T
Other languages
English (en)
Inventor
Armin Lahm
Gennaro Ciliberto
Carlo Toniatti
Rocco Savino
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of DK0745094T3 publication Critical patent/DK0745094T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
DK95940409T 1994-12-14 1995-12-13 Superagonister og antagonister mod human IL-6 og fremgangsmåder til deres udvælgelse DK0745094T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM940805A IT1274782B (it) 1994-12-14 1994-12-14 Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
PCT/IT1995/000216 WO1996018648A1 (en) 1994-12-14 1995-12-13 Superagonists and antagonists of h il-6, and 3d modelling method for their selection

Publications (1)

Publication Number Publication Date
DK0745094T3 true DK0745094T3 (da) 2003-06-10

Family

ID=11402859

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95940409T DK0745094T3 (da) 1994-12-14 1995-12-13 Superagonister og antagonister mod human IL-6 og fremgangsmåder til deres udvælgelse

Country Status (13)

Country Link
US (2) US5849283A (da)
EP (1) EP0745094B1 (da)
JP (2) JP3206919B2 (da)
CN (1) CN1070866C (da)
AT (1) ATE234864T1 (da)
AU (1) AU702783B2 (da)
CA (1) CA2177838A1 (da)
DE (1) DE69529973T2 (da)
DK (1) DK0745094T3 (da)
ES (1) ES2192585T3 (da)
IT (1) IT1274782B (da)
PT (1) PT745094E (da)
WO (1) WO1996018648A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016202A1 (en) * 1995-10-27 1997-05-09 Amrad Operations Pty. Ltd. Cytokines and their use in treatment and/or prophylaxis of breast cancer
JP3824173B2 (ja) * 1995-11-07 2006-09-20 株式会社カネカ 自己抗原
IT1285790B1 (it) 1996-09-24 1998-06-24 Angeletti P Ist Richerche Bio Adenovirus difettivi ricombinanti che codificano per mutanti di interleuchina 6 umana (hil-6) con attivita' antagonista o
AUPO439396A0 (en) 1996-12-24 1997-01-23 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment and prophylaxis
GB9702944D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
ES2312184T3 (es) 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
CA2237915A1 (en) * 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
WO2000001404A1 (en) 1998-07-06 2000-01-13 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for $i(in vitro) fertilization
JP4799516B2 (ja) * 1998-08-24 2011-10-26 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する膵炎の予防又は治療剤
ES2276525T3 (es) 1998-08-24 2007-06-16 Chugai Seiyaku Kabushiki Kaisha Preventivos o remedios para la pancreatitis que contienen anticuerpos anti-receptor il-6 como ingrediente activo.
US6541244B1 (en) * 1999-06-07 2003-04-01 Cedars-Sinai Medical Center Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans
WO2001016166A2 (en) * 1999-08-27 2001-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polypeptides, comprising il-6 ligand-binding receptor domains, and related nucleic acids, antibodies, compositions, and methods of use
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
RU2318829C2 (ru) * 2001-11-14 2008-03-10 Сентокор, Инк. Антитела против il-6, композиции, способы и применение
US20060165683A1 (en) 2001-12-05 2006-07-27 Gerard Karsenty Methods and compositions for control of bone formation via modulation of sympathetic tone
CA2516945A1 (en) 2003-02-24 2004-09-02 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for spinal cord injury comprising interleukin-6 antagonist
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
RU2554942C2 (ru) 2003-10-17 2015-07-10 Тугаи Сейяку Кабусики Кайся Терапевтический агент для мезотелиомы
US20050100550A1 (en) * 2003-11-10 2005-05-12 Mohit Trikha Anti-angiogenic uses of IL-6 antagonists
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
AU2006300234B2 (en) 2005-10-14 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (ja) 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
EP3135298B1 (en) 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
KR101508019B1 (ko) 2007-01-23 2015-04-06 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 만성 거부반응 억제제
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
US8188235B2 (en) * 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
EP2578233B1 (en) 2010-05-28 2017-04-26 National Cancer Center Therapeutic agent for pancreatic cancer
SI2578231T1 (sl) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Okrepljen protitumorski T celični odzivnik
EP2787007A3 (en) 2010-11-08 2015-03-11 F. Hoffmann-La Roche AG Subcutaneously administered ANTI-IL-6 receptor antibody
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
EP2898896A1 (en) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
TWI873632B (zh) 2015-02-27 2025-02-21 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
WO2020213665A1 (ja) 2019-04-17 2020-10-22 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2147466A1 (en) * 1992-10-20 1994-04-28 Just P. J. Brakenhoff Interleukin-6 receptor antagonists
IT1263022B (it) * 1992-11-06 1996-07-23 Angeletti P Ist Richerche Bio Interleuchina-6 mutante con attivita' biologica migliorata rispetto all'interleuchina-6 selvatica.

Also Published As

Publication number Publication date
AU702783B2 (en) 1999-03-04
EP0745094A1 (en) 1996-12-04
CN1070866C (zh) 2001-09-12
US5849283A (en) 1998-12-15
AU4187196A (en) 1996-07-03
CN1140456A (zh) 1997-01-15
HK1011032A1 (en) 1999-07-02
CA2177838A1 (en) 1996-06-15
JPH09502460A (ja) 1997-03-11
WO1996018648A1 (en) 1996-06-20
DE69529973T2 (de) 2003-12-04
JP3206919B2 (ja) 2001-09-10
JP3286310B2 (ja) 2002-05-27
JP2001354698A (ja) 2001-12-25
PT745094E (pt) 2003-07-31
ITRM940805A1 (it) 1996-06-14
ATE234864T1 (de) 2003-04-15
ES2192585T3 (es) 2003-10-16
EP0745094B1 (en) 2003-03-19
IT1274782B (it) 1997-07-24
DE69529973D1 (de) 2003-04-24
ITRM940805A0 (it) 1994-12-14
US5914106A (en) 1999-06-22

Similar Documents

Publication Publication Date Title
ATE234864T1 (de) Superagonisten und antagonisten von humanen il-6 und methoden zu deren selektion
DE69636720D1 (de) Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung
DE60125381D1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
NO891711L (no) Hiv env-kodet peptid som er istand til aa fremkalle hiv-inhiberende antistoffer i pattedyr.
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
DE69519748D1 (de) Aus den vorstufen des mage tumor-abstossungsantigen abstammende einzelne peptede, die hla-a2 moleküle komplexieren
NO20013608L (no) DNA-klon for human vevsfaktorinhibitor
ATE170192T1 (de) Zusammensetzungen und methoden zur synthese des b-rezeptors für das natriuretische protein und verwendungsmethoden
DE69627150T2 (de) Verfahren zur herstellung von gegen e.coli bakterien der familie cs4-cfa/1 gerichteten antikörpern
DE69228749D1 (de) Neuartige polypeptide und ihre verwendung
DK0656117T3 (da) Fremgangsmåde til udvælgelse af superagonister, antagonister og superantagonister for interleukin 6
PT1148065E (pt) Proteínas de fusão
ATE299182T1 (de) Polynukleotide und polypeptide aus pathogenen mycobakterien und deren verwendung als diagnostika, impfstoffe und als ziel der chemotherapie
GB2399819A (en) Method of transducing es cells
BG97042A (bg) Метод за получаване на растения,резистентни към атаките на sсlеrотiniа sсlеrотiоruм,чрез внасяне на ген,кодиращ оксалатоксидаза
Leong et al. Cloning and expression of the cDNA for bovine granulocyte-macrophage colony-stimulating factor
ES8207511A1 (es) Un procedimiento para la preparacion de nuevos peptidos.
EP0330700A4 (en) Human prourokinase-like polypeptide.
DE69939586D1 (de) Inhibitoren für die gefässneubildung
DK0876610T3 (da) Fremgangsmåde og anvendelse af polypeptid i sædcelle-æg-binding til at foröge eller mindske fertilitet
DK0977859T3 (da) Den neurotrofiske faktor NNT-1
DE69932804D1 (de) Protein, welches durch einen cystinknoten charakterisiert ist und verfahren zu dessen herstellung
EP0832109A4 (en) FACTOR-2, HOMOLOGY OF THE FIBROBLASTS GROWTH FACTOR AND METHOD FOR ITS APPLICATION
ATE141947T1 (de) Klonierung eines neuen mitgliedes der familie der fibroblasten-wachstumsfaktoren (fgf)-rezeptoren
DK0938555T3 (da) Konstruktioner og komplekser af cyclin E